For the year ending 2025-12-31, ACRV had $1,686K increase in cash & cash equivalents over the period. -$65,334K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -77,905 |
| Depreciation expense | 1,356 |
| Stock-based compensation expense | 14,720 |
| Non-cash operating lease expense | 1,027 |
| Net amortization of premiums and accretion of discounts on investments | 437 |
| Prepaid expenses and other current assets | -190 |
| Accounts payable | 1,536 |
| Accrued expenses and other liabilities | -3,353 |
| Operating lease liabilities | -936 |
| Other assets | -137 |
| Net cash used in operating activities | -63,665 |
| Purchases of investments | 81,731 |
| Proceeds from maturities of investments | 149,500 |
| Purchases of property and equipment | 1,669 |
| Net cash provided by (used in) investing activities | 66,100 |
| Proceeds from exercise of stock options | 1 |
| Payments of tax withholdings related to vesting of restricted stock units | 750 |
| Net cash (used in) provided by financing activities | -749 |
| Net increase in cash, cash equivalents, and restricted cash | 1,686 |
| Cash, cash equivalents and restricted cash at beginning of period | 40,016 |
| Cash, cash equivalents and restricted cash at end of period | 41,702 |
Acrivon Therapeutics, Inc. (ACRV)
Acrivon Therapeutics, Inc. (ACRV)